Within its last year performance, BDTX rose by 16.82%, with highs and lows ranging from $6.75 to $1.20, whereas the simple moving average jumped by 3.76% in the last 200 days.
On July 01, 2025, Raymond James started tracking Black Diamond Therapeutics Inc (NASDAQ: BDTX) recommending Outperform. A report published by Raymond James on July 31, 2024, Initiated its previous ‘Outperform’ rating for BDTX. Stifel June 30, 2023d the rating to Buy on June 30, 2023, and set its price target from $2 to $10. H.C. Wainwright June 28, 2023d its ‘Neutral’ rating to ‘Buy’ for BDTX, as published in its report on June 28, 2023. Wedbush’s report from June 27, 2023 suggests a price prediction of $10 for BDTX shares, giving the stock a ‘Outperform’ rating. Wedbush also rated the stock as ‘Neutral’.
Analysis of Black Diamond Therapeutics Inc (BDTX)
Black Diamond Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 4.14% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.24, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and BDTX has an average volume of 1.15M. On a monthly basis, the volatility of the stock is set at 7.14%, whereas on a weekly basis, it is put at 6.49%, with a gain of 0.81% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.33, showing growth from the present price of $2.5, which can serve as yet another indication of whether BDTX is worth investing in or should be passed over.
How Do You Analyze Black Diamond Therapeutics Inc Shares?
Biotechnology giant Black Diamond Therapeutics Inc (BDTX) is based in the USA and is one of the largest companies in the market. When comparing Black Diamond Therapeutics Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 40.52, there is a growth in quarterly earnings of 378.68%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 23.88%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 61.96% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BDTX shares are owned by institutional investors to the tune of 61.96% at present.
